Please refer to Important Dosing and Administration Information. (PDF)

For immediate assistance or questions regarding the dosage and administration of HyperRAB™ S/D, Rabies Immune Globulin (Human) please call 919.412.1030.

HyperRAB™ S/D 2 mL prefilled syringes have been distributed only in the United States.

View Prescribing Information (PDF)

The products discussed herein may only be dispensed with a prescription from a doctor or healthcare provider.

Patients often present to medical centers following contact with an animal suspected of being infected with rabies. Post-exposure treatment of animal-related wounds should encompass adequate wound care and rabies immunoprophylaxis to prevent onset of symptoms. Emergency room staff must develop an awareness of both regional epidemiological trends in animal rabies and local health department treatment recommendations that encourage optimal post-exposure treatment in all cases of potential rabies exposure.

Recommended Use of HyperRAB™ S/D

Indicated for post-exposure prophylaxis in persons requiring treatment. A regimen including both HyperRAB™ S/D and rabies vaccine will provide both short-term and long-term protection. HyperRAB™ S/D should be administered as promptly as possible after exposure, but may be given through the seventh day after the first dose of rabies vaccine is given. The circumstances of biting incident, type of exposure, vaccination status of biting animal, and presence of rabies in region, should be taken into consideration.

Recommendations for use of passive and active immunization after exposure to an animal suspected of having rabies have been detailed by the U.S. Public Health Service Advisory Committee on Immunization Practice (ACIP).

For short-term, passive, transient post-exposure prevention of rabies infection.

For Intramuscular Administration Only.

Product Attributes

			Solvent/Detergent treatment for virus removal/inactivation (See Product Insert [PDF])
			Pre-filled vials for single-use IM injection only
			Tamper-evident packaging

Contraindications, side effects, and precautions

			Use caution in persons with a history of prior systemic allergic reaction to human immune globulin products or a history of IgA deficiency
			The most common side effects reported are slight soreness at the site of injection and slight temperature elevation
			Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after rabies immune globulin (human) administration

Rabies Information

Rabies is a viral infection that affects the central nervous system. It is generally transmitted from animal to human through a bite or exposure of broken skin to the animal's saliva.

Rabies infection produces a number of symptoms, including fever, acute excitation, convulsions, excess salivation, insomnia, anxiety, difficult swallowing, or maniacal behavior.

Rabies is fatal unless treated with rabies immune globulin along with the rabies vaccine to prevent infection caused by the virus. Rabies immune globulin works by providing the body's immune system with antibodies necessary to protect against the virus until it can produce its own antibodies.

For immediate assistance or questions regarding the dosage and administration of HyperRAB™ S/D, Rabies Immune Globulin (Human) please call 919.412.1030.

HyperRAB™ S/D 2 mL prefilled syringes have been distributed only in the United States.


Important Safety Information

			HyperRAB S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.
			The attending physician who wishes to administer HyperRAB S/D to person with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.
			As with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.
			Soreness at the site of injection and mild temperature elevations may be observed at times. Sensitization to repeated injections has occurred occasionally in immunoglobulin-deficient patients. Angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock have rarely been reported after intramuscular injection so that a causal relationship between immunoglobulin and these reactions is not clear.
			Administration of live virus vaccines (e.g., MMR) should be deferred for approximately 3 months after Rabies immune globulin (human) administration.
			As with all plasma-directed therapeutics, the potential to transmit infectious agents, such as viruses, cannot be totally eliminated.